Eun Ji Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eun Ji Lee has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Suhwan Chang
Department of Physiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
5 shared publications - Min Jeong Cha
Department of Physiology, BK21 Project, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea
2 shared publications - Pil Kim
Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea
2 shared publications - Bo Hyun Moon
Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea
1 shared publication - Chae Won Yu
Department of Physiology, BK21 Project, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea
1 shared publication - Dae-Yeon Cho
Neogenlogic Inc., Seongnam-si, Gyeongi-do, Republic of Korea
1 shared publication
Latest Publications
- Open Access
Development of a Cost-Effective, Heme-Tolerant Bovine Muscle Cell for Cultivated Meat Production
One of the critical requirements for the production of artificial meat is to mimic the flavor of the original meat. Therefore, incorporation of heme has been proposed, but it is toxic when added at high concentrations in cell culture systems. Additionally, obtaining heme can be costly depending on the source. In this study, we aimed to support the growth of normal bovine muscle cells (BRMC-F2401, BRMCs) by introducing a bacterial extract obtained from a safe, high-heme-containing Corynebacterium species. The BRMCs exhibited heme toxicity when the bacterial heme level was >20 μM; however, they were adapted to stably proliferate with a 3 on–3 off culture scheme. RNA sequencing of the heme-adapted BRMCs showed gene expression changes, including upregulation of detoxification genes, CYP1A1, CYP26B1, and SERPINB2. The knockdown of these three genes increased heme sensitivity and reversed heme tolerance of the heme-adapted BRMCs. Additionally, ROS levels increased upon heme treatment, suggesting that ROS is an important factor in heme adaptation processes. Collectively, our study presents an affordable strategy to incorporate heme in cultured meat production and the mechanism underlying this process.
Open AccessDevelopment of a Cost-Effective, Heme-Tolerant Bovine Muscle Cell for Cultivated Meat Production
One of the critical requirements for the production of artificial meat is to mimic the flavor of the original meat. Therefore, incorporation of heme has been proposed, but it is toxic when added at high concentrations in cell culture systems. Additionally, obtaining heme can be costly depending on the source. In this study, we aimed to support the growth of normal bovine muscle cells (BRMC-F2401, BRMCs) by introducing a bacterial extract obtained from a safe, high-heme-containing Corynebacterium species. The BRMCs exhibited heme toxicity when the bacterial heme level was >20 μM; however, they were adapted to stably proliferate with a 3 on–3 off culture scheme. RNA sequencing of the heme-adapted BRMCs showed gene expression changes, including upregulation of detoxification genes, CYP1A1, CYP26B1, and SERPINB2. The knockdown of these three genes increased heme sensitivity and reversed heme tolerance of the heme-adapted BRMCs. Additionally, ROS levels increased upon heme treatment, suggesting that ROS is an important factor in heme adaptation processes. Collectively, our study presents an affordable strategy to incorporate heme in cultured meat production and the mechanism underlying this process.
- Open Access
- 5 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (49) , eadx8303
B cell–reactive neoantigens boost antitumor immunity
B cell involvement in neoantigen-driven antitumor immunity remains largely unexplored because of challenges in predicting B cell responses. Here, we developed a method to identify B cell epitopes by characterizing >437,000 peptides tested for IgG binding and >370 million B cell receptor (BCR) clones. Our single-cell BCR sequencing of pre– and post–severe acute respiratory syndrome coronavirus 2 vaccination validates the performance of this method. Mouse vaccination experiments demonstrate that B cell neoepitopes enhance immune responses, driving BCR expansion and tumor regression. Genomic analysis of >8000 The Cancer Genome Atlas (TCGA) samples reveals an inverse correlation between predicted B cell reactivity and mutation allele frequencies, indicating B cell–mediated neoantigen elimination. Applying our multiomics model to checkpoint blockade responses in 2074 patients highlights the clinical relevance of B cell neoepitope prediction. A meta-analysis of 11 personalized vaccine trials involving 1739 neoantigens suggests that incorporating B cell neoepitopes may improve vaccination efficacy. These results underscore the significance of B cell–reactive neoantigens in antitumor immunity.
- 5 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (49) , eadx8303
Open AccessB cell–reactive neoantigens boost antitumor immunity
B cell involvement in neoantigen-driven antitumor immunity remains largely unexplored because of challenges in predicting B cell responses. Here, we developed a method to identify B cell epitopes by characterizing >437,000 peptides tested for IgG binding and >370 million B cell receptor (BCR) clones. Our single-cell BCR sequencing of pre– and post–severe acute respiratory syndrome coronavirus 2 vaccination validates the performance of this method. Mouse vaccination experiments demonstrate that B cell neoepitopes enhance immune responses, driving BCR expansion and tumor regression. Genomic analysis of >8000 The Cancer Genome Atlas (TCGA) samples reveals an inverse correlation between predicted B cell reactivity and mutation allele frequencies, indicating B cell–mediated neoantigen elimination. Applying our multiomics model to checkpoint blockade responses in 2074 patients highlights the clinical relevance of B cell neoepitope prediction. A meta-analysis of 11 personalized vaccine trials involving 1739 neoantigens suggests that incorporating B cell neoepitopes may improve vaccination efficacy. These results underscore the significance of B cell–reactive neoantigens in antitumor immunity.
- Open Access
- 27 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 5824
Development of a Normal Porcine Cell Line Growing in a Heme-Supplemented, Serum-Free Condition for Cultured Meat
A key element for the cost-effective development of cultured meat is a cell line culturable in serum-free conditions to reduce production costs. Heme supplementation in cultured meat mimics the original meat flavor and color. This study introduced a bacterial extract generated from Corynebacterium that was selected for high-heme expression by directed evolution. A normal porcine cell line, PK15, was used to apply the bacterial heme extract as a supplement. Consistent with prior research, we observed the cytotoxicity of PK15 to the heme extract at 10 mM or higher. However, after long-term exposure, PK15 adapted to tolerate up to 40 mM of heme. An RNA-seq analysis of these heme-adapted PK15 cells (PK15H) revealed a set of altered genes, mainly involved in cell proliferation, metabolism, and inflammation. We found that cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1), lactoperoxidase (LPO), and glutathione peroxidase 5 (GPX5) were upregulated in the PK15H heme dose dependently. When we reduced serum serially from 2% to serum free, we derived the PK15H subpopulation that was transiently maintained with 5–10 mM heme extract. Altogether, our study reports a porcine cell culturable in high-heme media that can be maintained in serum-free conditions and proposes a marker gene that plays a critical role in this adaptation process.
- 27 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 5824
Open AccessDevelopment of a Normal Porcine Cell Line Growing in a Heme-Supplemented, Serum-Free Condition for Cultured Meat
A key element for the cost-effective development of cultured meat is a cell line culturable in serum-free conditions to reduce production costs. Heme supplementation in cultured meat mimics the original meat flavor and color. This study introduced a bacterial extract generated from Corynebacterium that was selected for high-heme expression by directed evolution. A normal porcine cell line, PK15, was used to apply the bacterial heme extract as a supplement. Consistent with prior research, we observed the cytotoxicity of PK15 to the heme extract at 10 mM or higher. However, after long-term exposure, PK15 adapted to tolerate up to 40 mM of heme. An RNA-seq analysis of these heme-adapted PK15 cells (PK15H) revealed a set of altered genes, mainly involved in cell proliferation, metabolism, and inflammation. We found that cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1), lactoperoxidase (LPO), and glutathione peroxidase 5 (GPX5) were upregulated in the PK15H heme dose dependently. When we reduced serum serially from 2% to serum free, we derived the PK15H subpopulation that was transiently maintained with 5–10 mM heme extract. Altogether, our study reports a porcine cell culturable in high-heme media that can be maintained in serum-free conditions and proposes a marker gene that plays a critical role in this adaptation process.
- Open Access
- 16 March 2023
- Published by Elsevier in Molecules and Cells
- Vol. 46 (6) , 351-359
RNA Editing Enzyme ADAR1 Suppresses the Mobility of Cancer Cells via ARPIN
Min Ji Park, Eunji Jeong, Eun Ji Lee, Hyeon Ji Choi, Bo Hyun Moon, Keunsoo Kang, and Suhwan Chang. Mol. Cells 2023;46:351-9. https://doi.org/10.14348/molcells.2023.2174
- 16 March 2023
- Published by Elsevier in Molecules and Cells
- Vol. 46 (6) , 351-359
Open AccessRNA Editing Enzyme ADAR1 Suppresses the Mobility of Cancer Cells via ARPIN
Min Ji Park, Eunji Jeong, Eun Ji Lee, Hyeon Ji Choi, Bo Hyun Moon, Keunsoo Kang, and Suhwan Chang. Mol. Cells 2023;46:351-9. https://doi.org/10.14348/molcells.2023.2174
- Open Access
siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model
Pancreatic cancer is characterized by late detection, frequent drug resistance, and a highly metastatic nature, leading to poor prognosis. Antibody-based immunotherapy showed limited success for pancreatic cancer, partly owing to the low delivery rate of the drug into the tumor. Herein, we describe a poly(lactic-co-glycolic acid;PLGA)-based siRNA nanoparticle targeting PD-L1 (siPD-L1@PLGA). The siPD-L1@PLGA exhibited efficient knockdown of PD-L1 in cancer cells, without affecting the cell viability up to 6 mg/mL. Further, 99.2% of PDAC cells uptake the nanoparticle and successfully blocked the IFN-gamma-mediated PD-L1 induction. Consistently, the siPD-L1@PLGA sensitized cancer cells to antigen-specific immune cells, as exemplified by Ovalbumin-targeting T cells. To evaluate its efficacy in vivo, we adopted a pancreatic PDX model in humanized mice, generated by grafting CD34+ hematopoeitic stem cells onto NSG mice. The siPD-L1@PLGA significantly suppressed pancreatic tumor growth in this model with upregulated IFN-gamma positive CD8 T cells, leading to more apoptotic tumor cells. Multiplex immunofluorescence analysis exhibited comparable immune cell compositions in control and siPD-L1@PLGA-treated tumors. However, we found higher Granzyme B expression in the siPD-L1@PLGA-treated tumors, suggesting higher activity of NK or cytotoxic T cells. Based on these results, we propose the application of siPD-L1@PLGA as an immunotherapeutic agent for pancreatic cancer.
Open AccesssiRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model
Pancreatic cancer is characterized by late detection, frequent drug resistance, and a highly metastatic nature, leading to poor prognosis. Antibody-based immunotherapy showed limited success for pancreatic cancer, partly owing to the low delivery rate of the drug into the tumor. Herein, we describe a poly(lactic-co-glycolic acid;PLGA)-based siRNA nanoparticle targeting PD-L1 (siPD-L1@PLGA). The siPD-L1@PLGA exhibited efficient knockdown of PD-L1 in cancer cells, without affecting the cell viability up to 6 mg/mL. Further, 99.2% of PDAC cells uptake the nanoparticle and successfully blocked the IFN-gamma-mediated PD-L1 induction. Consistently, the siPD-L1@PLGA sensitized cancer cells to antigen-specific immune cells, as exemplified by Ovalbumin-targeting T cells. To evaluate its efficacy in vivo, we adopted a pancreatic PDX model in humanized mice, generated by grafting CD34+ hematopoeitic stem cells onto NSG mice. The siPD-L1@PLGA significantly suppressed pancreatic tumor growth in this model with upregulated IFN-gamma positive CD8 T cells, leading to more apoptotic tumor cells. Multiplex immunofluorescence analysis exhibited comparable immune cell compositions in control and siPD-L1@PLGA-treated tumors. However, we found higher Granzyme B expression in the siPD-L1@PLGA-treated tumors, suggesting higher activity of NK or cytotoxic T cells. Based on these results, we propose the application of siPD-L1@PLGA as an immunotherapeutic agent for pancreatic cancer.